English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: The aim of this study was to compare the pharmacokinetic parameters between two brands of pregabalin in healthy Chilean volunteers.    Methods: A randomized, single-dose, two-period, two-sequence, crossover study design with a 2-week washout period was conducted in healthy Chilean males. Plasma samples were collected over a 12-hour period after administration of 150 mg pregabalin in each period. A validated ultra-performance liquid chromatography with positive ionization mass spectrometric detection method was used to analyze pregabalin concentration in plasma. Pharmacokinetic parameters were determined using a noncompartmental method. Bioequivalence between the test and reference products was determined when the ratio for the 90% confidence intervals (CIs) of the difference in the means of the log-transformed area under the curve (AUC) 0-t , AUC 0-∞ , and maximum concentration (C max ) of the two products were within 0.80 and 1.25.    Results: The study was carried out on 22 healthy Chilean volunteers. The mean (SD) C max , AUC 0-t  and AUC 0-∞  of the test formulation (Pregobin TM ) of pregabalin were 2.10 (0.56) µg/ml, 10.35 (2.00) µgxh/ml and 13.92 (2.74) µgxh/ml, respectively. The mean (SD) C max , AUC 0-t  and AUC 0- ∞  of the reference formulation (Lyrica TM ) of pregabalin were 2.15 (0.52) µg/ml, 10.31 (1.85) µgxh/ml and 13.78 (2.25) µgxh/ml, respectively. The parametric 90% CIs for C  max , AUC 0-t , and AUC 0-∞  were 0.97—1.13, 1.01—1.04, and 0.98—1.02, respectively.    Conclusions: These results suggest that both products are bioequivalent and can be used as interchangeable options in the clinical setting.

A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers